Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
12-week boceprevir triple therapy for acute HCV genotype 1 in HIV-coinfected patients
NL-OMON40134Phase 3Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Aug 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of boceprevir in hepatitis C virus infection, human immunodeficiency virus infection (HIV), sponsored by Erasmus MC. Started Aug 2013; status: active, not recruiting.
02
Drugs
boceprevir
03
Conditions
hepatitis C virus infectionhuman immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NL-OMON40134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40134.